作者: M. Ilie , E. Long , V. Hofman , B. Dadone , C.H. Marquette
关键词:
摘要: ABSTRACT Background Non-small-cell lung carcinoma (NSCLC) patients with a BRAFV600E mutation benefit from targeted therapy. The usefulness of immunohistochemistry (IHC) as an alternative approach for the detection in NSCLC has not been evaluated until now. This study compared specificity and sensitivity IHC other methods primary adenocarcinoma. Patients BRAF mutations were analysed by DNA sequencing Caucasian subpopulation selected 450 1509 (30%) EGFR, KRAS, PI3KA, Her2 EML4-ALK wild-type (wt) adenocarcinomas. Detection was carried out using VE1 clone antibody results molecular methodologies. Results Of (9%) tumours, 40 harboured mutation, which corresponded to either or non-BRAFV600E 21 (5%) 19 (4%) cases, respectively. assay positive (90%) BRAFV600E-mutated tumours negative all BRAFnonV600E-mutated tumours. Conclusion is specific sensitive method may be biology NSCLC.